secwatch.observer — SEC 8-K summary
======================================

Issuer:     Editas Medicine, Inc. (EDIT)
CIK:        0001650664
Form:       8-K
Filed at:   2024-02-28T23:59:59+00:00
Accession:  0001650664-24-000006
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Editas reports Q4 net loss of $18.9M; Vertex license deal provides cash runway into 2026
--------------------------------------------------------------------------------

- Q4 net loss $18.9M ($0.23 per share) vs $60.7M ($0.88) in Q4 2022; revenue boosted by Vertex license.
- Cash $427.1M as of Dec 31, 2023; with Vertex license payments, runway expected into 2026.
- FDA aligns that RUBY trial is single Phase 1/2/3 to support BLA; adolescent cohort enrollment initiated.
- Entered license agreement with Vertex for Cas9 for ex vivo SCD/beta thal; $50M contingent upfront plus annual fees.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000006/0001650664-24-000006-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650664/000165066424000006/edit-20240228.htm
  HTML page:      https://secwatch.observer/filing/0001650664-24-000006

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer